Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
Paediatric Clinic, University Hospital Brno, Medical Faculty of Masaryk University, Brno, Czech Republic.
Eur J Pediatr. 2018 Dec;177(12):1837-1844. doi: 10.1007/s00431-018-3255-2. Epub 2018 Sep 24.
Diarrhea-associated hemolytic uremic syndrome is characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury secondary to enteric infection, typically Shiga toxin-producing Escherichia coli. Shiga toxin 2 is able to activate alternative complement pathways; therefore, the aim of the study was to analyze C3 as a predictor of clinical courses in patients with diarrhea-associated hemolytic uremic syndrome. We hypothesized that the patients with increased complement activation at admission suffered from a more severe course. We retrospectively analyzed data of 33 pediatric patients between 1999 and 2015 in the Czech Republic. We tested the association of a C3 concentration with biochemical parameters and the clinical data reflecting the severity of the disease. We found significant correlation between the initial C3 and the duration of renal replacement therapy (r = - 0.62, p = 0.0001) and the initial glomerular filtration rate (r = 0.36, p = 0.026). Patients with C3 < 0.825 g/L needed renal replacement therapy and also had significantly more renal complications (p = 0.015).Conclusion: Based on our study, decreased C3 concentrations can be used as one of the risk factors that can help predict the need for acute dialysis and a more severe course of disease in children with diarrhea-associated hemolytic uremic syndrome. What is Known: • Shiga toxin modulates the function of complement regulatory proteins and thus contributes to complement activation in patients with diarrhea-associated hemolytic uremic syndrome. • Risk factors that can predict the need for acute renal replacement therapy and poor outcome in patients with diarrhea-associated hemolytic uremic syndrome are mainly the combination of oligoanuria, dehydration, leukocytosis, high hematocrit > 23%, and neurological involvement. What is New: • A lowered concentration of C3 at the time of initial presentation of diarrhea-associated hemolytic uremic syndrome was associated with more severe renal failure and the need for renal replacement therapy along with the development of more extra renal complications. • Decreased C3 at admission can predict complicated course of diarrhea-associated hemolytic uremic syndrome.
腹泻相关性溶血尿毒综合征的特征为溶血性贫血、血小板减少和继发于肠感染的急性肾损伤,通常由产志贺毒素大肠埃希菌引起。志贺毒素 2 能够激活替代补体途径;因此,本研究旨在分析 C3 作为腹泻相关性溶血尿毒综合征患者临床病程的预测因子。我们假设入院时补体激活增加的患者病情更严重。我们回顾性分析了 1999 年至 2015 年捷克共和国 33 名儿科患者的数据。我们检测了 C3 浓度与反映疾病严重程度的生化参数和临床数据之间的关联。我们发现初始 C3 与肾脏替代治疗持续时间(r = -0.62,p = 0.0001)和初始肾小球滤过率(r = 0.36,p = 0.026)之间存在显著相关性。C3 < 0.825 g/L 的患者需要肾脏替代治疗,并且肾脏并发症显著更多(p = 0.015)。结论:基于我们的研究,C3 浓度降低可作为预测儿童腹泻相关性溶血尿毒综合征患者需要急性透析和疾病更严重病程的危险因素之一。已知情况:• 志贺毒素调节补体调节蛋白的功能,从而有助于腹泻相关性溶血尿毒综合征患者的补体激活。• 能够预测腹泻相关性溶血尿毒综合征患者需要急性肾替代治疗和不良预后的危险因素主要是少尿、脱水、白细胞增多、高血细胞比容>23%和神经系统受累的组合。新发现:• 腹泻相关性溶血尿毒综合征初始表现时 C3 浓度降低与更严重的肾衰竭和需要肾脏替代治疗以及更多肾外并发症的发展相关。• 入院时 C3 降低可预测腹泻相关性溶血尿毒综合征的复杂病程。